Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo
The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Background Hyperthermic intraperitoneal (IP) chemotherapy after cytoreduction improves survival in patients with colorectal carcinomatosis of the peritoneal surface. Most protocols use single agents (mitomycin C or oxaliplatin) provided IP. The purpose of this study was to determine whether combination IP chemotherapy is superior to single-agent therapy in a mouse model. Methods Nu/Nu mice were injected IP with HT-29 colorectal cancer cells. Animals were treated with single agents or combinations. Primary end point was overall survival. Agents explored included oxaliplatin, mitomycin C, panitumumab, erlotinib, cetuximab, and irinotecan delivered IP as single agents; mitomycin C, panitumumab, and irinotecan in combination IP; and 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) in combination delivered intravenously. Results Survival of mice receiving irinotecan or mitomycin C IP was greater than controls. Median survival of mice receiving intravenous FOLFIRI was also greater than control. However, survival of mice receiving IP irinotecan or mitomycin C was far greater than mice receiving intravenous FOLFIRI. For combination therapy, a positive interaction was observed with mitomycin C and irinotecan, whereas survival was greater than either agent individually. No interaction was observed between panitumumab and mitomycin C or irinotecan. However, an overall survival benefit was observed with the combination of irinotecan, mitomycin C, and panitumumab; at 120 days after cell inj…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapy comprising MMC has improved animal model outcomes and shown additional survival benefits for CC patients [7].”
From Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer (2024) · cites this paper as [7]
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“instead, mutation in the downstream signaling mediator, KRAS, predicted outcome such that disease of patients with activating mutations of KRAS did not respond to panitumumab.(35) Subsequent studies have further demonstrated that mutational status of several molecules in the EGFR signaling cascade, including PI3KCA an…”
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Sadeghi, B., Arvieux, C., Glehen, O., Beaujard, A. C., Rivoire, M., Baulieux, J., Fontaumard, E., Brachet, A., Caillot, J. L., Faure, J. L., et al. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o · Cited by 1,200
Glehen, O., Kwiatkowski, F., Sugarbaker, P. H., Elias, D., Levine, E. A., De Simone, M., Barone, R., Yonemura, Y., Cavaliere, F., Quenet, F., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.012 · Cited by 1,184 · cited 5×
“This study further had a trend toward higher survival rates in patients receiving both hyperthermic therapy during surgery together with postoperative IP therapy compared with patients receiving either treatment alone.(11) Although these differences were not statistically significant, this finding may indicate that mu…”
Influential(2011) · Hepatogastroenterology · doi:10.5754/hge11069 · Cited by 1,140
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Verwaal, V. J., Bruin, S., Boot, H., van Slooten, G., & van Tinteren, H. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9966-2 · Cited by 1,033 · cited 4×
“This viewpoint has been supported by reports documenting median survival of patients with peritoneal dissemination to be between 5.2 and 7 months.5–7 Previously presented as an oral presentation at SSO’s 62nd Annual Cancer Symposium, March 5–8, 2009, Phoenix, AZ. Society of Surgical Oncology 2009 First Received: 4 Mar…”
Influential
Research works printed but not linked: 1
- Cavaliere F, Valle M, De Simone M, et al. 120 peritoneal carcinomatoses from colorectal cancer treated with peritonectomy and intra-abdominal chemohyperthermia: a SITILO multicentric study. In Vivo. 2006;20:747–50.
Cited by
Prada-Villaverde, A., Esquivel, J., Lowy, A. M., Markman, M., Chua, T., Pelz, J., Baratti, D., Baumgartner, J. M., Berri, R., Bretcha-Boix, P., et al. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23728 · Cited by 163
“Irinotecan, MMC, and Panitumumab: at 120 days after cell injection, 100% of the tri‐agent therapy group survived [12].”
BackgroundAuer, R. C., Sivajohanathan, D., Biagi, J. J., Conner, J., Kennedy, E. D., & May, T. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.10.034 · Cited by 98
Noura, S., Ohue, M., Shingai, T., Kano, S., Ohigashi, H., Yano, M., Ishikawa, O., Takenaka, A., Murata, K., & Kameyama, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1319-2 · Cited by 54
“Furthermore, combination IP therapy with MMC, panitumumab, and irinotecan was superior to all other agents tested alone or in combination.(39) However, with regard to the combination IPC, further phase I clinical trials will be necessary to integrate into clinical practice.”
BackgroundSelection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer
Braam, H. J., Schellens, J. H. M., Boot, H., van Sandick, J. W., Knibbe, C. A. J., Boerma, D., & van Ramshorst, B. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.04.004 · Cited by 33
“The efficacy of intraperitoneal irinotecan has been demonstrated in several animal studies [88–91] In the largest study in humans no statistically significant difference was noted in survival after CRS + HIPEC using oxaliplatin with or without irinotecan in 146 colorectal patients with established…”
The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series
Saif, M. W., Kontny, E., Syrigos, K., & Shahrokni, A. (2011) · Journal of Oncology · doi:10.1155/2011/125467 · Cited by 27
“Combined intraperitoneal chemotherapy of panitumumab, mitomycin-C, and irinotecan also showed efficacy in colorectal carcinomatosis in vivo [21].”
Background
Metadata
- Authors
- Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F.
- Affiliations
- University of Kansas Medical Center (US)
- Corresponding author
- Roby, Katherine F.
- Venue
- Annals of Surgical Oncology
- Published
- 2009-08-26
- Volume
- 17
- Issue
- 1
- Pages
- 296-303
- ISSN
- 1068-9265 (ISSN-L)
- 1534-4681
- OpenAlex
- W1966510780
- Cited by
- 17
- References
- 73
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2020: 1 · 2016: 2 · 2015: 2 · 2014: 2 · 2013: 4
- FWCI
- 0.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Annals of Surgical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- intraperitoneal chemotherapy, combination chemotherapy, mitomycin C, oxaliplatin, irinotecan, panitumumab, cetuximab, erlotinib, FOLFIRI, cytoreduction, hyperthermic intraperitoneal chemotherapy, mouse model, overall survival
- MeSH terms
- Cetuximab, Erlotinib Hydrochloride, Irinotecan, Oxaliplatin, Panitumumab, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Injections, Intraperitoneal, Mice, Nude, Organoplatinum Compounds, Quinazolines, Tumor Cells, Cultured, Colorectal Neoplasms, Survival Rate, Mitomycin, Treatment Outcome, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo. https://app.cochat.ai/papers/10.1245/s10434-009-0669-0
- The paper
- Cohen, M. S., Al-kasspooles, M. F., Williamson, S. K., Henry, D., Broward, M., & Roby, K. F. (2010). Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-009-0669-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.